Form 4: SpringWorks Therapeutics COO Disposes of Equity Holdings Following Merck KGaA Merger Completion

SpringWorks Therapeutics' Chief Operating Officer, Edris Badreddin, disposed of all beneficial ownership in the company's securities, including common stock, restricted stock units, performance share units, and stock options, as a result of the company's acquisition by Merck KGaA for $47.00 per share.

Summary

• SpringWorks Therapeutics, Inc. (SWTX) completed its merger with Merck KGaA, Darmstadt, Germany, through its subsidiary EMD Holdings Merger Sub, Inc., effective July 1, 2025.
• As a result of the merger, SpringWorks Therapeutics became a wholly-owned subsidiary of Merck KGaA.
• Edris Badreddin, the Chief Operating Officer of SpringWorks Therapeutics, disposed of all his beneficial ownership in the company's securities on July 1, 2025.
• This disposition included 169,712 shares of common stock, which incorporated 66,931 shares underlying restricted stock units (RSUs).
• Additionally, 33,778 performance share units (PSUs) were disposed of.
• A total of 692,298 shares underlying various stock options with exercise prices ranging from $1.65 to $43.00 were also disposed of.
• Each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash.
• Outstanding RSUs and PSUs, whether vested or unvested, were cancelled and converted into cash-based awards, calculated by multiplying the number of shares subject to the award by the $47.00 merger consideration.
• Vested stock options were cancelled and converted into cash equal to the product of the number of shares subject to the option and the excess of the $47.00 merger consideration over the option's exercise price.
• Unvested stock options were cancelled and converted into cash-based option awards, calculated similarly to vested options.
• Cash-based RSU and option awards will generally vest according to their original terms, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger's closing date, subject to continued employment with Parent.
• Any outstanding stock options with an exercise price greater than $47.00 per share were cancelled at the effective time of the merger for no consideration.

Sentiment

Score: 7

Explanation: The sentiment is positive as the merger successfully closed, providing a cash payout to shareholders and converting equity awards into cash or cash-based awards for employees, indicating a successful exit for the company and its investors.

Positives

• Shareholders received a cash consideration of $47.00 per share for their common stock holdings.
• Equity awards (RSUs, PSUs, and stock options) were converted into cash or cash-based awards, providing liquidity to holders.
• A portion of unvested cash-based RSU and option awards will vest on the nine-month anniversary of the merger, subject to continued employment, providing a retention incentive.

Negatives

• Stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no payment, resulting in a loss for holders of those specific options.

Risks

• The risk of stock options being out-of-the-money (exercise price greater than merger consideration) was realized, leading to their cancellation without payment.

Future Outlook

Unvested cash-based RSU and option awards will continue to vest according to their original terms, with a specific acceleration of 50% of unvested tranches on the nine-month anniversary of the merger's closing date, contingent on the holder's continued employment with Merck KGaA.

Industry Context

This transaction represents a significant M&A event in the biopharmaceutical sector, where larger pharmaceutical companies often acquire smaller, innovative biotech firms to expand their pipelines and market presence. The acquisition of SpringWorks Therapeutics by Merck KGaA aligns with this trend, indicating consolidation and strategic portfolio enhancement within the industry.

Comparison to Industry Standards

• The acquisition price of $47.00 per share for SpringWorks Therapeutics common stock reflects a valuation determined through negotiation, typical for M&A transactions in the biopharmaceutical industry.
• The conversion of equity awards (RSUs, PSUs, stock options) into cash or cash-based awards with continued vesting provisions is a standard practice in mergers to ensure continuity and retention of key personnel post-acquisition, similar to deals seen with companies like Celgene (acquired by Bristol-Myers Squibb) or Medivation (acquired by Pfizer).

Corporate Governance

Related Party Transactions

• The merger itself constitutes a transaction with Merck KGaA, which became the new parent company of SpringWorks Therapeutics.

Stakeholder Impact

• Shareholders: Received $47.00 per share in cash, realizing their investment.
• Employees (including the COO): Equity awards were converted to cash or cash-based awards, with continued vesting contingent on employment, providing financial benefit and retention incentives.
• Company (SpringWorks Therapeutics): Transitioned from a publicly traded entity to a wholly-owned subsidiary, integrating into Merck KGaA's operations.

Next Steps

• Continued employment of the Chief Operating Officer with Merck KGaA to facilitate the vesting of cash-based RSU and option awards.
• The vesting of 50% of each then-unvested tranche of cash-based RSU and option awards on the nine-month anniversary of the merger's closing date.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock Units, Performance Share Units, Cash-Based Awards, Corporate Governance